Skip to main content

Pachyonychia Congenita

0
Pipeline Programs
1
Companies
5
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Palvella Therapeutics
4 programs
PTX-022PHASE_2_31 trial
PTX-022PHASE_32 trials
PTX-022PHASE_31 trial
QTORIN 3.9% rapamycin anhydrous gelPHASE_31 trial
Active Trials
NCT03920228Completed73Est. Oct 2020
NCT07552077Recruiting15Est. Sep 2027
NCT05643872Recruiting45Est. Nov 2023
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Palvella TherapeuticsPTX-022
Palvella TherapeuticsQTORIN 3.9% rapamycin anhydrous gel
Palvella TherapeuticsPTX-022
Palvella TherapeuticsPTX-022
Palvella TherapeuticsPTX-022

Clinical Trials (5)

Total enrollment: 256 patients across 5 trials

A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita

Start: Nov 2022Est. completion: Nov 202345 patients
Phase 3Recruiting
NCT05180708Palvella TherapeuticsQTORIN 3.9% rapamycin anhydrous gel

A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita

Start: Nov 2021Est. completion: Jun 202387 patients
Phase 3Completed

VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita

Start: Sep 2020Est. completion: Dec 202236 patients
Phase 3Completed

Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita

Start: Apr 2019Est. completion: Oct 202073 patients
Phase 2/3Completed

A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)

Start: Apr 2026Est. completion: Sep 202715 patients
Phase 2Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 256 patients
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.